Acadian Asset Management
ORMP icon

Acadian Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Acadian Asset Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8K Sell
1,691
-13,375
-89% -$53.2K ﹤0.01% 1951
2026
Q1 		$50K Buy
+15,066
New +$51.1K ﹤0.01% 1855
2023
Q3 		– Sell
-31,736
Closed -$113K – 1785
2023
Q2 		$113K Buy
+31,736
New +$102K ﹤0.01% 1383

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management's ORMP Position: Q2 2026 in Review

Acadian Asset Management reduced its Oramed Pharmaceuticals (ORMP) stake by 89% in Q2 2026, selling an estimated $53.2K and leaving 1,691 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1951.

Acadian Asset Management first reported a position in ORMP in Q2 2023 and has held it in 3 quarters since. The position peaked at $113K in Q2 2023. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Acadian Asset Management held 1,691 shares of Oramed Pharmaceuticals worth $8K as of Q2 2026.
  • Acadian Asset Management sold 13,375 Oramed Pharmaceuticals shares in Q2 2026, an estimated $53.2K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1951 holding.
  • Acadian Asset Management first reported a position in Oramed Pharmaceuticals in Q2 2023 and has held it in 3 quarters since.
  • Acadian Asset Management's Oramed Pharmaceuticals position peaked at $113K in Q2 2023.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.